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Summary 
Depression contributes substantially to disease burden worldwide; however despite of 
this, the progress in understanding its pathophysiology has been extremely slow and the 
discovery of new therapeutic mechanisms is at a near standstill. The molecular targets of current 
major classes of antidepressants were all reverse engineered from drugs previously discovered 
by serendipitous clinical observations. Since the existence of adult-born neurons was 
unequivocally documented, adult neurogenesis became a very promising, but also very hyped 
target for antidepressant drugs. Introduction of corticotrophin releasing hormone inhibitors 
aimed to exploit a prospective reduction of glucocorticoid-mediated inhibition of adult 
neurogenesis with the aim to produce antidepressant effect. Although these drugs failed to 
demonstrate efficiency in phase three clinical trials, they provided the following valuable 
lesions for the future: (1) Inter-species differences between animals and humans should be 
considered very carefully, (2) Animal model phenotypes mimicking depression should be more 
robust, preferably shown by multiple behavioral paradigms, and (3) variability between 
different subgroups of depression should be taken into consideration because of the pronounced 
heterogeneity of the disease. 
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Adult neurogenesis 
Neurogenesis is the process of generation and differentiation of stem and 
progenitor cells into mature neurons. The peak of neurogenesis occurs in embryonic 
stage, when the brain gets populated by the majority of the neurons; this occurs in 
embryonic days 14 and 15 in mice and between 11th and 14th postcoital week in humans 
(1). After the initial round of apoptotic selection, these cells continue the maturation, 
transforming themselves into fully functional and branched neurons. Under assumption 
that the neuronal development went without difficulties causing neurodevelopmental 
disorders, these neurons will serve their physiological role in adulthood enabling the 
correct function of the central nervous system (CNS). Until recently, the general attitude 
in neuroscience was that no new neurons are formed in the adulthood in humans, 
despite of the fact that the proof for adult neurogenesis in rodents was present in the 
field for a long time (2). This changed by the end of the last century, when the nuclei of 
the hippocampal neurons of the cancer patients treated with bromodeoxyuridin (BRDU) 
were found positive for this cytostatic (3). This finding demonstrated that these neurons 
were created after the initiation of BRDU treatment, and represented a clear proof for 
the existence of adult neurogenesis in humans. 
After the existence of adult neurogenesis was ascertained throughout all 
mammalian species, the field has focused the efforts into revealing of its role. One of 
the starting points was the restricted spatial locus of the adult neurogenesis; it occurs 
only in the subependymal layer of the ventricular zone (SVZ) and the subgranular zone 
of the hippocampal dentate gyrus in rodents, while in humans the presence of newly 
born neurons is only proved to occur in hippocampus (3) and recently in striatum (4,5). 
The other starting point was the assumption that the normal function of adult 
neurogenesis must reflect the normal function of the brain, while the disturbances in its 
function could lead to the adaptive, or potentially maladaptive, changes in CNS 
function. However, the difficulties in analyzing the living human brain lead to the 
standstill in the research of molecular mechanism of adult neurogenesis, causing the 
shift in research to the animal models.  
A single analogy was the driving force to connect the adult neurogenesis and 
affective disorders. Neurodevelopmental disorders emerge as a result of the impairment 
of embryonic neurogenesis and they usually manifest very early in life, whereas the 
affective disorders usually start to be apparent only in the adulthood. Under the 
assumption that both of these classes of CNS disorders have similarities in their 
etiology, impairment in adult neurogenesis could lead to the rise of affective disorders 
in adulthood. The following series of facts were supporting this hypothesis.  
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Role of the hippocampus 
Despite intensive research on the function of the hippocampus there is still some 
controversy about the basic functions of this structure. Based on the series of correlation 
studies, evidence is emerging of the involvement of the hippocampal formation in a 
wide range of psychiatric disorders including Alzheimer’s disease, schizophrenia, 
anxiety disorders and depression (6,7). The hippocampus is considered a part of the 
limbic system and humans and other mammals having two hippocampi, one in each 
hemisphere. Hippocampal role in the formation of memory is widely known and 
generally accepted in the field (8,9). However it also seems to be critically important in 
regulation of emotions as well (10,11) and it furthermore seems important in regulating 
the stress response (12). The HC is one of the most connected areas in the brain, 
receiving its major input from the entorhinal cortex through the perforant pathway. The 
entorhinal cortex serves as the major connector between the hippocampus and several 
different cortical areas including the auditory and olfactory cortices, but also the 
amygdala (6) indicating that the hippocampal function can be sensitive to external, 
potentially stressful stimuli. Indeed, hippocampal neurons express glucocorticoid 
receptors (13), while the prolonged exposure to stress paradigms results in 
glucocorticoid-mediated reduction in hippocampal size, dendritic branching, and adult 
neurogenesis (12). 
Association between major depression and stress 
Major depressive disorder (MDD) is a common, heterogeneous affective disorder 
with a life-time prevalence of approximately 17 % (14,15), and it represents the most 
prevalent psychiatric disorder. The association between stress and MDD is a very 
consistent finding in psychiatry; however, none of the negative environmental factors is 
sufficient to predict MDD. Therefore, the association between stress and adult 
neurogenesis, on its own, is not enough to make any conclusion about the role of adult 
neurogenesis in the etiology of MDD. A series of studies based on animal models gave 
strength to the hypothesis that the ablation in adult neurogenesis is responsible, at least 
in part, for MDD. The therapy of MDD consists of drugs of many classes mainly 
focused on the increase of monoaminergic neurotransmission. All these treatment 
classes were found to increase adult neurogenesis in animal models (16). In addition to 
the antidepressants, behaviors proven to participate in healthy ways of coping in stress 
and to be helpful in MDD treatment, such as an increase in physical activity (17) and 
enriched environment (18) were also found to increase adult neurogenesis.  
Chronic CORT treatment in mice causes changes in mRNA levels of Fkbp5 and 
Nr3c1, and a decrease in Fkbp5 DNA methylation in the hippocampus (19), as well as 
the anxious and depressive phenotype (19,20). Similar FKBP5 and NR3C1 gene 
methylation and expression changes are following stressful events throughout life in 
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humans and are correlated with the onset of MDD (21,22). These similarities in the 
molecular changes in the brain of a mouse and a human is by no means sufficient proof 
that mice can be depressed; however, they indicate translational potential of the research 
of molecular stress mediators from mice to humans. 
CRF1 inhibitors as candidate drugs for major depression 
Chronic treatment with fluoxetine is proven to be able to ameliorate 
anxiety/depression CORT-induced changes in various behavioral paradigms in CORT 
treated mice (23); this fluoxetine effect is proven to be dependent on intact hippocampal 
neurogenesis (20,23,24). Corticotrophin release factor (CRF) inhibitors were shown to 
ameliorate anxiety/depression phenotypes independently of neurogenesis in the 
hippocampus (24) suggesting that the antidepressant effect of the monoaminergic 
neurotransmission can be mediated by the suppression of the HPA axis. This hypothesis 
was facilitated by human data, since the cerebrospinal fluid of depressed patients was 
found to contain elevated levels of the CRF long time ago (25). Hippocampus was 
found to be involved in the stress feedback loop where glucocorticoid-sensitive 
hippocampal neurons terminating the adrenocortical stress response (26) and the 
newborn neurons in the hippocampus could facilitate this pathway. This is one of the 
mechanisms which counter balances glucocorticoid positive feedback loop on CRF 
synthesis and secretion, responsible for maintaining the organism responsive to acute 
stressors under conditions of chronic stress (27). This mechanism would also explain 
the long incubation period until the onset of the antidepressant action, since the increase 
in hippocampal neurogenesis would take time to develop mature neurons able to 
participate in HPA inhibition. Hypothetically, CRF inhibitors would skip this feedback 
loop and potentially decrease the time needed for monamine-based antidepressants to 
act making them very good candidate drugs for the new generation antidepressants. 
CRF1 receptors, which are predominantly expressed in rodent CNS unlike CRF2 
receptor (28), were also shown to mediate the anxiolytic effects in animal models in 
pharmacological (24) and genetic studies (29). Therefore, selective CRF1 antagonists 
could block excessive HPA axis signaling caused by the elevated CRF in the spinal 
fluid of depressed patients and were speculated to be very promising antidepressant 
candidates. 
Negative results of the clinical studies and the aftermath 
Backed up by the corticosteroid receptor hypothesis of the depression (30), 
pharmaceutical industry started to develop CRF1 blockers a decade ago. Since peptidic 
compounds were not able to penetrate throughout blood-brain barrier, the focus of the 
field was on non-peptidic small molecules. The initial results were encouraging in 
general (31); the escalating doses of R121919 normalized sleep electroencephalography 
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and reduced depressive and anxious symptoms in depressed patients in early clinical 
trials (32). However, R121919 development was discontinued because of elevated liver 
enzymes, reversible after treatment discontinuation in a parallel trial (33). Since then, 
many more CRF1 inhibitors entered clinical trials; however, no subsequent compound 
has successfully completed a definitive Phase III trial due to the lack of efficiency in 
results in double-blind, placebo-controlled trials for MDD (34,35). These discouraging 
results lowered the further effort pharmaceutical companies invested in the development 
of novel compounds blocking CRF1 and it decreased the faith in the results obtained 
from animal models for mood disorders in general. This event also contributed to the 
general trend of gradual withdrawal of pharmaceutical companies from the research 
focused on affective disorders. 
Conclusions and future directions 
Keeping in mind the cost of developing novel compounds in pharmaceutical 
industry, it is crucial to prevent these types of miss-investments if possible. The 
explanation of the negative results from phase III clinical studies can have various 
reasons. 
The limitation in translational potential of mouse data to humans is maybe the 
most obvious limitation of preclinical studies involving animal models. Errors in the 
research including animal models can be divided in two groups. (A) Objective 
limitations in these studies originate from the differences between two organisms, 
which are especially emphasized for the higher brain functions. Some behavioural 
aspects, such as suicidal thoughts, cannot even be ascertained in animals. In addition, it 
is impossible to be certain if the same biochemical pathways are behind the same 
behaviours in rodents and humans, and if the adaptive mechanisms causing 
antidepressant-like response in rodents are in fact equivalent to the antidepressant action 
in humans. This can sometimes lead to the misinterpretation of the animal results in 
humans. CRF2 receptors are not present in the rodent brain (28), while in human brain 
they are (36). If this fact was not neglected, it might have had directed the industry not 
to base their research exclusively on CRF1 receptor. Assuming that the CRF2 receptor 
is not relevant for antidepressant effect was derived from the conclusion that it is not 
relevant for antidepressant-like effect in mice despite of the known differences in the 
receptor profile in the brain between species. (B) Methodological limitations in the 
animal behavior research are also numerous. Anxiety, for example, can be measured in 
rodents by various behavioral essays; it is unknown if they measure the same aspect of 
anxiety in animals and it is unclear which one, or ones, is the most appropriate to use for 
testing a specific hypothesis (37). Frequent, but wrong, practice in behavioral research 
is to base conclusions on positive results derived from only one of these test. Due to the 
publishing bias, it is not rare that the negative results from some of these paradigms 
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remain unpublished, despite of the fact that they could serve as a valuable data in 
assessment of the success chance of the clinical study. 
Next, the limited knowledge about the mood disorders, namely MDD, is 
interfering with the selection of the relevant groups for the clinical studies. The wrong 
selection of treatment groups can then imply false negative results for the efficiency in a 
clinical trial, despite the possible antidepressant efficiency of the drug in the defined 
subgroup of patients. High MDD prevalence in general population together with the fact 
that no SNP achieved genome-wide significant association with MDD using the present 
GWAS sample sizes (38) underlines the fact that MDD is a very heterogeneous disease. 
Under these conditions, it is possible that CRF1 inhibitors could be very effective 
treatment of a group selected by closely defined criteria and that this effect is diluted 
and remained undetected in the randomized group of MDD patients. 
Taken together, despite of the insufficient antidepressant efficiency of CRF1 
inhibitors in general MDD patient population, they might still be effective in a specific 
subgroup of MDD patients, namely the subset of patients with the elevated CRF in 
cerebrospinal fluid. New technical developments and diagnostic tools might eventually 
lead to a more successful treatment of major depression with CRF1 receptor blockers. 
The proofs of the involvement of adult neurogenesis in the hippocampus in stress 
perception and antidepressant effect are abundant. The role of newborn neurons is 
probably not confined only to the regulation of HPA axis and it might induce 
antidepressant effect through other pathways. 
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Kratak sadržaj 
Iako depresija značajno doprinosi morbiditetu na globalnom nivou, napredak u 
razumevanju patofiziologije ove bolesti je izuzetno spor, pa su posledično, otkrića novih 
terapeutskih mehanizama praktično u zastoju. Ciljni molekuli preko kojih deluju antidepresivi 
koji su danas u upotrebi identifikovani su reverznim inženjeringom lekova otkrivenih 
empirijski, kliničkim zapažanjima. Otkad je jasno pokazano postojanje novonastalih neurona, 
adultna neurogeneza je postala izuzetno atraktivna potencijalna meta delovanja kandidata za 
antidepresivne lekove. Uvođenje inhibitora kortikotropin-oslobađajućeg hormona imalo je za 
cilj da se iskoristi činjenica da glukokortikoidni hormoni inhibiraju adultnu neurogenezu i time 
doprinose antisdepresivnom efektu. Iako su se ovi lekovi pokazali kao neefikasni u trećoj fazi 
kliničkih studija, naučene su sledeće važne lekcije za budućnost: (1) razlike u funkcionisanju 
mozga ljudi i životinja moraju biti pažljivo razmotrene, (2) da bi se zaključilo da animalni 
model ima depresivni fenotip, isti je potrebno ubedljivo demonstrirati, po mogućstvu 
korišćenjem većeg broja bihejvioralnih testova i (3) varijacije u simptomima između različitih 
podklasa depresije treba uzeti u obzir imajući u vidu heterogenost oboljenja. 
 
Ključne reči:  Depresija, Stres, Hipokampus, Adultna neurogeneza,  
Glukokortikoidna signalizacija 
 
